Novartis shares slide 9% after del‑desiran trial disappointment
The Swiss drugmaker’s stock fell sharply on Tuesday as investors reacted to lackluster data from its del‑desiran study, adding to a string of recent trial setbacks.
Novartis AG saw its shares tumble about 9% on Tuesday following a disappointing read‑out from the Phase III trial of its experimental therapy del‑desiran, CNBC reported. The setback joins two other recent trial failures that have weighed on the company’s pipeline momentum.
The del‑desiran compound, still in development, was being evaluated for an indication that has long eluded effective treatment. While the exact therapeutic target was not disclosed in the brief, the trial’s lack of statistically significant improvement over placebo triggered a sharp sell‑off among investors who had been counting on the drug to bolster the firm’s growth outlook.
Novartis, one of the world’s largest pharmaceutical firms, has been navigating a transition from legacy blockbusters to a pipeline driven by specialty medicines and biologics. In recent years, the company has invested heavily in gene‑editing, oncology and rare‑disease programs, hoping to offset the inevitable decline of older products as patents expire. A series of trial disappointments can strain that strategic shift, as each missed milestone delays potential revenue streams and may prompt analysts to revise earnings forecasts.
Historically, the market reacts swiftly to clinical trial outcomes because they serve as a proxy for future cash flow. A 9% drop places Novartis among a broader cohort of pharma stocks that have experienced volatility after late‑stage trial results this year, underscoring the high‑risk nature of drug development. Investors typically reassess the company’s risk profile, weighing the cost of ongoing research against the probability of eventual approval.
Looking ahead, Novartis will need to demonstrate progress elsewhere in its pipeline to restore confidence. The firm has several candidates in late‑stage testing for oncology and immunology indications, and any positive data from those studies could help offset the current disappointment. Meanwhile, analysts will be watching the company’s upcoming earnings call for guidance on how the del‑desiran setback will affect its 2027 revenue projections and R&D budgeting.
The episode highlights the broader challenge facing big‑pharma: balancing the promise of innovative therapies with the inherent uncertainty of clinical trials. As Novartis works to navigate this setback, the broader market will be keen to see whether its diversified pipeline can deliver the next wave of growth.
This report is based on original reporting by CNBC. Read the original source →